UP

Samsung will also produce cancer drugs

Home page World
12 Punto 14 Punto 16 Punto 18 Punto

Samsung Biologics Co Ltd said on Monday it would continue its partnership with AstraZeneca Plc on manufacturing biopharmaceuticals.

Axar.az reports that Samsung said production of drug substance and drug products is valued at about $380 million, up from the initial $331 million after the companies expanded the deal this year in May 2021.

The company said it would start to manufacture a cancer immunotherapy product from next year along with AstraZeneca’s COVID-19 long-acting antibody (LAAB) combination, AZD7442.

Samsung Biologics CEO John Rim said, “We are delighted to continue expanding our strategic collaboration with AstraZeneca, a valuable partner we have witnessed first-hand to have a strong commitment to saving lives of patients”.

Date
2021.12.14 / 15:12
Author
Axar.az
See also

Germany plans to buy additional F-35 fighter jets

At least 9 bus passengers killed by terrorists in Pakistan

EU weighs suspending Israel ties over Gaza crisis

Russia downs 155 Ukrainian drones

Trump to use presidential authority to send weapons to Kyiv

Desperate Putin might resort to nukes

EU grants Ukraine €2.3B aid

Zelensky: Meeting with Putin possible after exchange

No Putin-Biden meeting planned - Rubio

Fire erupts at Italian tourist camp: 600 evacuated

Latest
Xocalı soyqırımı — 1992-ci il Bağla
Bize yazin Bağla
ArxivBağla